Lenalidomide in combination with intravenous ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Lenalidomide in combination with intravenous rituximab (revri) in relapsed/refractory primary cns lymphoma or primary intraocular lymphoma: a multicenter prospective "
Auteur(s) :
Ghesquieres, Herve [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Chevrier, M. [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Laadhari, M. [Auteur]
Chinot, O. [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Choquet, Sylvain [Auteur]
CIC AP-HP (pitie-Salpetriere)/inserm
Molucon-Chabrot, Cecile [Auteur]
Service d’Hématologie Biologique [CHU Clermont-Ferrand]
Beauchesne, P. [Auteur]
Centre Hospitalier Universitaire de Nancy [CHU Nancy]
Gressin, R. [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Schmitt, Anna [Auteur]
Institut Bergonié [Bordeaux]
Gyan, E. [Auteur]
Centre Hospitalier Régional Universitaire de Tours [CHRU Tours]
Hoang-Xuan, K. [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Nicolas-Virelizier, Emmanuelle [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Cassoux, N. [Auteur]
Institut Curie [Paris]
Touitou, V. [Auteur]
Le Garff-Tavernier, M. [Auteur]
Savignoni, A. [Auteur]
Institut Curie [Paris]
Turbiez, I. [Auteur]
Soumelis, V. [Auteur]
Immunité et cancer [U932]
Houillier, C. [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Soussain, Carole [Auteur]
Institut Curie [Paris]
Université Claude Bernard Lyon 1 [UCBL]
Chevrier, M. [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Laadhari, M. [Auteur]
Chinot, O. [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Choquet, Sylvain [Auteur]
CIC AP-HP (pitie-Salpetriere)/inserm
Molucon-Chabrot, Cecile [Auteur]
Service d’Hématologie Biologique [CHU Clermont-Ferrand]
Beauchesne, P. [Auteur]
Centre Hospitalier Universitaire de Nancy [CHU Nancy]
Gressin, R. [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Schmitt, Anna [Auteur]
Institut Bergonié [Bordeaux]
Gyan, E. [Auteur]
Centre Hospitalier Régional Universitaire de Tours [CHRU Tours]
Hoang-Xuan, K. [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Nicolas-Virelizier, Emmanuelle [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Cassoux, N. [Auteur]
Institut Curie [Paris]
Touitou, V. [Auteur]
Le Garff-Tavernier, M. [Auteur]
Savignoni, A. [Auteur]
Institut Curie [Paris]
Turbiez, I. [Auteur]
Soumelis, V. [Auteur]
Immunité et cancer [U932]
Houillier, C. [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Soussain, Carole [Auteur]
Institut Curie [Paris]
Titre de la revue :
Annals of Oncology
Nom court de la revue :
Ann. Oncol.
Numéro :
30
Pagination :
621-628
Date de publication :
2019-04
ISSN :
1569-8041
Mot(s)-clé(s) en anglais :
primary vitreoretinal lymphoma
lenalidomide
rituximab
primary CNS lymphoma
relapse
lenalidomide
rituximab
primary CNS lymphoma
relapse
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Primary central nervous system lymphomas (PCNSLs) are mainly diffuse large B-cell lymphomas (DLBCLs) of the non-germinal center B-cell (non-GCB) subtype. This study aimed to determine the efficacy of rituximab plus ...
Lire la suite >Primary central nervous system lymphomas (PCNSLs) are mainly diffuse large B-cell lymphomas (DLBCLs) of the non-germinal center B-cell (non-GCB) subtype. This study aimed to determine the efficacy of rituximab plus lenalidomide (R2) in DLBCL-PCNSL. Patients with refractory/relapsed (R/R) DLBCL-PCNSL or primary vitreoretinal lymphoma (PVRL) were included in this prospective phase II study. The induction treatment consisted of eight 28-day cycles of R2 (rituximab 375/m2 i.v. D1; lenalidomide 20 mg/day, D1-21 for cycle 1; and 25 mg/day, D1-21 for the subsequent cycles); in responding patients, the induction treatment was followed by a maintenance phase comprising 12 28-day cycles of lenalidomide alone (10 mg/day, D1-21). The primary end point was the overall response rate (ORR) at the end of induction (P0 = 10%; P1 = 30%). Fifty patients were included. Forty-five patients (PCNSL, N = 34; PVRL, N = 11) were assessable for response. The ORR at the end of induction was 35.6% (95% CI 21.9-51.2) in assessable patients and 32.0% (95% CI 21.9-51.2) in the intent-to-treat analysis, including 13 complete responses (CR)/unconfirmed CR (uCR; 29%) and 3 partial responses (PR; 7%). The best responses were 18 CR/uCR (40%) and 12 PR (27%) during the induction phase. The maintenance phase was started and completed by 18 and 5 patients, respectively. With a median follow-up of 19.2 months (range 1.5-31), the median progression-free survival (PFS) and overall survival (OS) were 7.8 months (95% CI 3.9-11.3) and 17.7 months (95% CI 12.9 to not reached), respectively. No unexpected toxicity was observed. The peripheral baseline CD4/CD8 ratio impacted PFS [median PFS = 9.5 months (95% CI, 8.1-14.8] for CD4/CD8 ≥ 1.6; median PFS = 2.8 months, [95% CI, 1.1-7.8) for CD4/CD8 < 1.6, P = 0.03). The R2 regimen showed significant activity in R/R PCNSL and PVRL patients. These results support assessments of the efficacy of R2 combined with methotrexate-based chemotherapy as a first-line treatment of PCNSL. NCT01956695.Lire moins >
Lire la suite >Primary central nervous system lymphomas (PCNSLs) are mainly diffuse large B-cell lymphomas (DLBCLs) of the non-germinal center B-cell (non-GCB) subtype. This study aimed to determine the efficacy of rituximab plus lenalidomide (R2) in DLBCL-PCNSL. Patients with refractory/relapsed (R/R) DLBCL-PCNSL or primary vitreoretinal lymphoma (PVRL) were included in this prospective phase II study. The induction treatment consisted of eight 28-day cycles of R2 (rituximab 375/m2 i.v. D1; lenalidomide 20 mg/day, D1-21 for cycle 1; and 25 mg/day, D1-21 for the subsequent cycles); in responding patients, the induction treatment was followed by a maintenance phase comprising 12 28-day cycles of lenalidomide alone (10 mg/day, D1-21). The primary end point was the overall response rate (ORR) at the end of induction (P0 = 10%; P1 = 30%). Fifty patients were included. Forty-five patients (PCNSL, N = 34; PVRL, N = 11) were assessable for response. The ORR at the end of induction was 35.6% (95% CI 21.9-51.2) in assessable patients and 32.0% (95% CI 21.9-51.2) in the intent-to-treat analysis, including 13 complete responses (CR)/unconfirmed CR (uCR; 29%) and 3 partial responses (PR; 7%). The best responses were 18 CR/uCR (40%) and 12 PR (27%) during the induction phase. The maintenance phase was started and completed by 18 and 5 patients, respectively. With a median follow-up of 19.2 months (range 1.5-31), the median progression-free survival (PFS) and overall survival (OS) were 7.8 months (95% CI 3.9-11.3) and 17.7 months (95% CI 12.9 to not reached), respectively. No unexpected toxicity was observed. The peripheral baseline CD4/CD8 ratio impacted PFS [median PFS = 9.5 months (95% CI, 8.1-14.8] for CD4/CD8 ≥ 1.6; median PFS = 2.8 months, [95% CI, 1.1-7.8) for CD4/CD8 < 1.6, P = 0.03). The R2 regimen showed significant activity in R/R PCNSL and PVRL patients. These results support assessments of the efficacy of R2 combined with methotrexate-based chemotherapy as a first-line treatment of PCNSL. NCT01956695.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
Université de Lille
Université de Lille
Collections :
Équipe(s) de recherche :
Modélisation biopharmaceutique et pharmacocinétique
Date de dépôt :
2019-12-16T14:06:43Z
2022-02-09T10:46:15Z
2022-02-09T10:46:15Z
Fichiers
- PIIS0923753419311184.pdf
- Version éditeur
- Accès restreint
- Accéder au document